Kura Oncology (KURA) 10-K 23 Feb 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2022	Feb. 17, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Trading Symbol	KURA
Entity Registrant Name	KURA ONCOLOGY, INC.
Entity Central Index Key	0001422143
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Public Float			$ 1.2
Entity Common Stock, Shares Outstanding		68,438,576
Entity File Number	001-37620
Entity Tax Identification Number	61-1547851
Entity Address, Address Line One	12730 High Bluff Drive
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92130
City Area Code	858
Local Phone Number	500-8800
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	true
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	San Diego, CA USA
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, subsequent to the date hereof pursuant to Regulation 14A in connection with the registrant ’ s 2023 Annual Meeting of Stockholders, are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxy statement will be filed with the SEC not later than 120 days after the conclusion of the registrant ’ s fiscal year ended December 31, 2022 .

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 51,802	$ 90,672
Short-term investments	386,183	427,288
Prepaid expenses and other current assets	8,441	4,329
Total current assets	446,426	522,289
Property and equipment, net	2,540	2,673
Restricted cash	210	210
Operating lease right-of-use assets	3,842	5,573
Other long-term assets	3,288	3,306
Total assets	456,306	534,051
Current liabilities:
Accounts payable and accrued expenses	21,739	20,192
Current operating lease liabilities	2,318	2,263
Total current liabilities	24,057	22,455
Long-term debt, net	9,158
Long-term operating lease liabilities	2,548	4,612
Other long-term liabilities	265	375
Total liabilities	36,028	27,442
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 200,000 shares authorized; 68,314 and 66,572 shares issued and outstanding as of December 31, 2022 and 2021, respectively	7	7
Additional paid-in capital	997,111	941,359
Accumulated other comprehensive income (loss)	(8,032)	(1,789)
Accumulated deficit	(568,808)	(432,968)
Total stockholders' equity	420,278	506,609
Total liabilities and stockholders' equity	$ 456,306	$ 534,051

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	68,314,000	66,572,000
Common stock, shares outstanding	68,314,000	66,572,000

STATEMENTS OF OPERATIONS AND CO

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Expenses:
Research and development	$ 92,812	$ 84,721	$ 60,397
General and administrative	47,053	46,537	31,502
Total operating expenses	139,865	131,258	91,899
Other Income (Expense):
Interest and other income, net	4,254	1,206	2,852
Interest expense	(229)	(414)	(578)
Total other income	4,025	792	2,274
Net Loss	$ (135,840)	$ (130,466)	$ (89,625)
Net loss per share, diluted	$ (2.03)	$ (1.97)	$ (1.69)
Net loss per share, basic	$ (2.03)	$ (1.97)	$ (1.69)
Weighted average number of shares used in computing net loss per share, basic	66,990	66,352	53,077
Weighted average number of shares used in computing net loss per share, diluted	66,990	66,352	53,077
Comprehensive Loss:
Net loss	$ (135,840)	$ (130,466)	$ (89,625)
Other comprehensive loss:
Unrealized loss on marketable securities and foreign currency	(6,243)	(1,835)	(285)
Comprehensive loss	$ (142,083)	$ (132,301)	$ (89,910)

STATEMENTS OF STOCKHOLDERS' EQU

STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid- In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2019	$ 218,781	$ 5	$ 431,322	$ 331	$ (212,877)
Beginning balance (in shares) at Dec. 31, 2019		45,384
Issuance of common stock, net of offering costs	458,978	$ 2	458,976
Issuance of common stock, net of offering costs, (in shares)		19,792
Share-based compensation expense	12,807		12,807
Issuance of common stock under equity plans	10,249		10,249
Issuance of common stock under equity plans (in shares)		1,018
Other comprehensive loss	(285)			(285)
Net loss	(89,625)				(89,625)
Ending balance at Dec. 31, 2020	610,905	$ 7	913,354	46	(302,502)
Ending balance (in shares) at Dec. 31, 2020		66,194
Share-based compensation expense	23,579		23,579
Issuance of common stock under equity plans	4,426		4,426
Issuance of common stock under equity plans (in shares)		378
Other comprehensive loss	(1,835)			(1,835)
Net loss	(130,466)				(130,466)
Ending balance at Dec. 31, 2021	506,609	$ 7	941,359	(1,789)	(432,968)
Ending balance (in shares) at Dec. 31, 2021		66,572
Issuance of common stock, net of offering costs	24,721		24,721
Issuance of common stock, net of offering costs, (in shares)		1,370
Share-based compensation expense	26,318		26,318
Issuance of common stock under equity plans	4,419		4,419
Issuance of common stock under equity plans (in shares)		372
Issuance of warrants in connection with debt facility	294		294
Other comprehensive loss	(6,243)			(6,243)
Net loss	(135,840)				(135,840)
Ending balance at Dec. 31, 2022	$ 420,278	$ 7	$ 997,111	$ (8,032)	$ (568,808)
Ending balance (in shares) at Dec. 31, 2022		68,314

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Activities
Net loss	$ (135,840)	$ (130,466)	$ (89,625)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	26,318	23,579	12,807
Amortization of premium and accretion of discounts on marketable securities, net	1,610	4,391	410
Depreciation expense	759	558	194
Non-cash interest expense	73	399
Loss from extinguishment of debt		212
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,935)	(357)	(711)
Operating lease right-of-use and other long-term assets	571	(329)	1,205
Accounts payable and accrued expenses	(802)	(2,518)	5,677
Other long-term liabilities	184	(20)	213
Net cash used in operating activities	(110,062)	(104,551)	(69,830)
Investing Activities
Maturities of marketable securities	303,908	319,969	223,198
Purchases of marketable securities	(270,655)	(445,657)	(320,963)
Purchases of property and equipment	(626)	(1,147)	(2,171)
Net cash provided by (used in) investing activities	32,627	(126,835)	(99,936)
Financing Activities
Proceeds from issuances of common stock, net	24,721		459,335
Proceeds from issuance of stock under equity plans	4,419	4,426	10,249
Proceeds from long-term debt	10,000
Payment of fees related to issuance of long-term debt	(575)
Repayment of long-term debt		(7,250)	(250)
Payment of fees related to extinguishment of debt		(611)
Net cash provided by (used in) financing activities	38,565	(3,435)	469,334
Net (decrease) increase in cash, cash equivalents and restricted cash	(38,870)	(234,821)	299,568
Cash, cash equivalents and restricted cash at beginning of period	90,882	325,703	26,135
Cash, cash equivalents and restricted cash at end of period	52,012	90,882	325,703
Supplemental disclosure of cash flow information:
Interest paid	73	$ 784	$ 419
Supplemental non-cash disclosures:
Warrants issued in connection with debt facility	$ 294

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule product candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment. We plan to advance our product candidates through a combination of internal development and strategic partnerships while maintaining significant development and commercial rights. References in these Notes to Financial Statements to “Kura Oncology, Inc.,” “we,” “our” or “us,” refer to Kura Oncology, Inc.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Reclassifications Certain prior period balances have been reclassified to conform to the current period presentation. Use of Estimates Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. We operate in a single industry segment which is the discovery and development of precision medicines for the treatment of cancer. Our chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment in the United States. Cash and Cash Equivalents Cash and cash equivalents consist of checking, money market and highly liquid investments that are readily convertible to cash and that have an original maturity of three months or less from date of purchase. The carrying amounts approximate fair value due to the short maturities of these instruments. Restricted Cash Under the terms of an office lease entered into in March 2020, we are required to maintain a standby letter of credit during the term of the lease. As of December 31, 2022 , restricted cash of $ 0.2 million was pledged as collateral for the letter of credit. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the balance sheets that sum to the total of the amounts shown on the statements of cash flows, in thousands: December 31, 2022 2021 2020 Cash and cash equivalents $ 51,802 $ 90,672 $ 325,493 Restricted cash 210 210 210 Total $ 52,012 $ 90,882 $ 325,703 Short-Term Investments Short-term investments are marketable securities with maturities greater than three months from date of purchase that are specifically identified to fund current operations. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund our operations, as necessary. The cost of short-term investments is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in interest income. Dividend and interest income is recognized as interest income on the statements of operations and comprehensive loss when earned. Short-term investments are classified as available-for-sale securities and carried at fair value with unrealized gains and non-credit related losses recorded in other comprehensive loss and included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities are determined on a specific identification basis and included in interest and other income, net on the statements of operations and comprehensive loss. Allowance for Credit Losses For available-for-sale securities in an unrealized loss position, we first assess whether we intend to sell, or if it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive loss on the statements of operations and comprehensive loss. We elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of our available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded in prepaid expenses and other current assets on our balance sheets. Our accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. Concentration of Credit Risk Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and placing investments with maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. Fair Value Measurements Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: • Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; • Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Computer software and equipment are depreciated over their estimated useful lives of three to five years . Laboratory equipment is depreciated over its estimated useful life of five years . Furniture and fixtures are depreciated over their estimated useful lives of five years . Leasehold improvements are depreciated over the lesser of the term of the related lease or the useful life of the asset. Impairment of Long-Lived Assets We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. For the years ended December 31, 2022, 2021 and 2020 , there were no impairments of the value of long-lived assets. Leases We determine if an arrangement is a lease or contains lease components at inception. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. For operating leases with an initial term greater than 12 months, we recognize operating lease right-of-use, or ROU, assets and operating lease liabilities based on the present value of lease payments over the lease term at commencement date. Operating lease ROU assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate when we are reasonably certain that the options will be exercised. We do not separate lease components from non-lease components. For our operating leases, we generally cannot determine the interest rate implicit in the lease, in which case we use our incremental borrowing rate as the discount rate for the lease. We estimate our incremental borrowing rate for our operating leases based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. If a lease is modified, the modified contract is evaluated to determine whether it is or contains a lease. If a lease continues to exist, the lease modification is determined to be a separate contract when the modification grants the lessee an additional ROU that is not included in the original lease and the lease payments increase commensurate with the standalone price for the additional ROU. A lease modification that results in a separate contract will be accounted for in the same manner as a new lease. For a modification that is not a separate contract, we reassess the lease classification using the modified terms and conditions and the facts and circumstances as of the effective date of the modification and recognize the amount of the remeasurement of the lease liability for the modified lease as an adjustment to the corresponding operating lease ROU asset. Research and Development Expenses Research and development expenses consist of costs associated with our research and development activities including salaries, benefits, share-based compensation and other personnel costs, clinical trial costs, manufacturing costs for non-commercial products, fees paid to external service providers and consultants, facilities costs and supplies, equipment and materials used in clinical and preclinical studies and research and development. All such costs are charged to research and development expense as incurred when these expenditures have no alternative future uses. We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed. Payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses in other research and development projects or otherwise, and therefore have no separate economic value, are expensed as research and development costs at the time such costs are incurred. As of December 31, 2022 , we had no in-licensed technologies that have alternative future uses in research and development projects or otherwise. Clinical Trial Costs and Accruals A significant portion of our clinical trial costs relate to contracts with contract research organizations, or CROs. The financial terms of our CRO contracts may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs concerning monthly expenses as well as reimbursement for pass through costs. We are also required to estimate certain of our expenses resulting from our obligations under our CRO contracts. Accordingly, our clinical trial expense accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. If the contracted amounts are modified, for instance, as a result of changes in the clinical trial protocol or scope of work to be performed, we modify our accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Historically, we have had no material changes in clinical trial expense that had a material impact on our results of operations or financial position. Patent Costs We expense all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications, and such costs are included in general and administrative expenses on the statements of operations and comprehensive loss. Share-Based Compensation Our share-based awards are measured at fair value on the date of grant based upon the estimated fair value of common stock. The fair value of awards expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award less actual forfeitures. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model, or Black-Scholes model, that requires the use of assumptions including volatility, expected term, risk-free rate and the fair value of the underlying common stock. We estimate the fair value of restricted stock units granted based on the closing market price of our common stock on the date of grant. Actual forfeitures are applied as they occur, and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited. Income Taxes Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. For uncertain tax positions that meet “a more likely than not” threshold, we recognize the benefit of uncertain tax positions in the financial statements. Comprehensive Loss Comprehensive loss is defined as the change in equity during the period from transactions and other events and non-owner sources. For the periods presented, accumulated other comprehensive loss consisted of unrealized gains and losses on marketable securities and foreign currency. Net Loss per Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock method. As we have reported net loss for the years ended December 31, 2022, 2021 and 2020, dilutive net loss per common share is the same as basic net loss per common share for those periods. Common stock equivalents outstanding are comprised of stock options, restricted stock units, warrants and employee stock purchase plan rights and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Common stock equivalents outstanding as of December 31, 2022, 2021 and 2020 totaling approximately 9,266,000 , 7,156,000 and 5,059,000 , respectively, were excluded from the computation of dilutive weighted-average shares outstanding because their effect would be anti-dilutive. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. We have evaluated recently issued accounting pronouncements and, based on our preliminary assessment, we do not believe any will have a material impact on our financial statements or related footnote disclosures.

Investments

Investments	12 Months Ended
	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Investments	3. Investments We invest in available-for-sale securities consisting of U.S. Treasury securities, corporate debt securities, commercial paper, money market funds, non-U.S. government debt securities, supranational debt securities and U.S. Agency bonds. Available-for-sale securities are classified as either cash and cash equivalents or short-term investments on the balance sheets. The following tables summarize, by major security type, our short-term investments that are measured at fair value on a recurring basis, in thousands: December 31, 2022 Maturities Amortized Unrealized Unrealized Estimated Fair Value Cash equivalents: Money market funds 1 or less $ 37,878 $ — $ — $ 37,878 U.S. Agency bonds 1 or less 9,956 — — 9,956 Total cash equivalents 47,834 — — 47,834 Short-term investments: U.S. Treasury securities 2 or less 183,051 16 ( 3,018 ) 180,049 Corporate debt securities 2 or less 115,763 — ( 3,931 ) 111,832 Commercial paper 1 or less 52,941 — — 52,941 Non-U.S. government and supranational debt securities 2 or less 26,268 — ( 950 ) 25,318 U.S. Agency bonds 1 or less 16,192 11 ( 160 ) 16,043 Total short-term investments 394,215 27 ( 8,059 ) 386,183 Total $ 442,049 $ 27 $ ( 8,059 ) $ 434,017 December 31, 2021 Maturities Amortized Unrealized Unrealized Estimated Fair Value Cash equivalents: Money market funds 1 or less $ 79,895 $ — $ — $ 79,895 Short-term investments: U.S. Treasury securities 3 or less 135,452 — ( 619 ) 134,833 Corporate debt securities 3 or less 208,064 — ( 892 ) 207,172 Commercial paper 1 or less 53,439 — — 53,439 Non-U.S. government and supranational debt securities 3 or less 23,122 — ( 214 ) 22,908 U.S. Agency bonds 2 or less 8,994 — ( 58 ) 8,936 Total short-term investments 429,071 — ( 1,783 ) 427,288 Total $ 508,966 $ — $ ( 1,783 ) $ 507,183 Short-term investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund our operations, as necessary. As of December 31, 2022 and 2021, short-term investm ents of $ 274.3 million and $ 246.9 million, respectively, had maturities less than one year, and short-term investments of $ 111.9 million and $ 180.4 million, respectively, had maturities between one to three years. Realized gains and losses were de minimis for the years ended December 31, 2022, 2021 and 2020. As of December 31, 2022 and 2021, 34 available-for-sale securities with a fair market value o f $ 290.0 million and 36 available-for-sale securities with a fair market value of $ 373.9 million, respectively, were in gross unrealized loss positions, $ 172.4 million and no ne of which were in a continuous unrealized loss position for greater than 12 months, respectively. We do not intend to sell these available-for-sale securities, and it is not more likely than not that we will be required to sell these securities prior to recovery of their amortized cost basis. Based on our review of these available-for-sale securities, the unrealized losses as of December 31, 2022 were primarily due to changes in interest rates and not due to increased credit risks associated with specific securities . We have no allowance for credit losses as of December 31, 2022 and 2021. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive loss. Accrued interest receivable on available-for-sale securities were $ 0.9 million and $ 1.4 million as of December 31, 2022 and 2021, respectively. We have not written off any accrued interest receivables for the years ended December 31, 2022, 2021 and 2020 .

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements As of December 31, 2022 and 2021, we had cash equivalents and short-term investments measured at fair value on a recurring basis. Available-for-sale securities consist of U.S. Treasury securities, which are measured at fair value using Level 1 inputs, and corporate debt securities, commercial paper, non-U.S. government debt securities, supranational debt securities and U.S. Agency bonds which are measured at fair value using Level 2 inputs. We determine the fair value of Level 2 related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. We validate the fair values of Level 2 financial instruments by comparing these fair values to a third-party pricing source. The following tables summarize, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy, in thousands: December 31, 2022 Total Level 1 Level 2 Cash equivalents: Money market funds $ 37,878 $ 37,878 $ — U.S. Agency bonds 9,956 — 9,956 Total cash equivalents 47,834 37,878 9,956 Short-term investments: U.S. Treasury securities 180,049 180,049 — Corporate debt securities 111,832 — 111,832 Commercial paper 52,941 — 52,941 Non-U.S. government and supranational debt securities 25,318 — 25,318 U.S. Agency bonds 16,043 — 16,043 Total short-term investments 386,183 180,049 206,134 Total $ 434,017 $ 217,927 $ 216,090 December 31, 2021 Total Level 1 Level 2 Cash equivalents: Money market funds $ 79,895 $ 79,895 $ — Short-term investments: U.S. Treasury securities 134,833 134,833 — Corporate debt securities 207,172 — 207,172 Commercial paper 53,439 — 53,439 Non-U.S. government and supranational debt securities 22,908 — 22,908 U.S. Agency bonds 8,936 — 8,936 Total short-term investments 427,288 134,833 292,455 Total $ 507,183 $ 214,728 $ 292,455 We believe that our term loan facility bears interest at a rate that approximates prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value of the term loan facility approximates fair value. The fair value of our term loan facility is determined using Level 2 inputs in the fair value hierarchy. See Note 6, Long-Term Debt, for further discussion of our term loan facility.

Balance Sheet Detail

Balance Sheet Detail	12 Months Ended
	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Detail	5. Balance Sheet Detail Property and equipment consisted of the following, in thousands: December 31, 2022 2021 Laboratory and computer equipment $ 1,568 $ 953 Leasehold improvements 1,543 1,532 Furniture and fixtures 1,032 1,032 Property and equipment, gross 4,143 3,517 Less: accumulated depreciation ( 1,603 ) ( 844 ) Property and equipment, net $ 2,540 $ 2,673 Depreciation expense was $ 0.8 million , $ 0.6 million and $ 0.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. Accounts payable and accrued expenses consisted of the following, in thousands: December 31, 2022 2021 Accounts payable $ 1,533 $ 3,236 Accrued clinical trial research and development expenses 2,440 2,619 Accrued other research and development expenses 5,030 5,341 Accrued compensation and benefits 10,300 7,923 Other accrued expenses 2,436 1,073 Total accounts payable and accrued expenses $ 21,739 $ 20,192

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt	6. Lo ng-Term Debt On November 2, 2022, we entered into a loan and security agreement, or Loan Agreement, with several banks and other financial institutions or entities party thereto, or collectively Lenders, and Hercules Capital, Inc., or Hercules, in its capacity as adminis trative agent and collateral agent for itself and the Lenders, or in such capacity, Agent. Under the terms of the Loan Agreement, we borrowed $ 10.0 million of an initial $ 25.0 million tranche of term loans, or the Tranche 1 Loan, and we may, at our sole discretion, borrow the remaining $ 15.0 million in respect of the Tranche 1 Loan at any time until September 15, 2023 . Thereafter, we may borrow (i) additional tranches of term loans in the amounts of up to $ 35.0 million, or the Tranche 2 Loan, and $ 40.0 million, or the Tranche 3 Loan, respectively, which will become available to us upon our satisfaction of certain terms and conditions set forth in the Loan Agreement, and (ii) a final tranche of term loans in the amount of up to $ 25.0 million, or the Tranche 4 Loan, subject to the Lenders’ investment committee approval in its sole discretion. All of the Term Loans have a maturity date of November 2, 2027 , or the Maturity Date. Repayment of the Term Loans is interest only through (a) initially, November 1, 2024 , (b) if we satisfy the Interest Only Milestone 1 Conditions (as defined in the Loan Agreement), May 1, 2025 , (c) if we satisfy the Interest Only Milestone 2 Conditions (as defined in the Loan Agreement), November 1, 2025 , and (d) if we satisfy the Approval Milestone (as defined in the Loan Agreement), November 1, 2026 . After the interest-only payment period, borrowings under the Loan Agreement are repayable in equal monthly payments of principal and accrued interest until the Maturity Date. The per annum interest rate for the Term Loans is the greater of (i) the prime rate as reported in The Wall Street Journal minus 6.25% plus 8.65% and (ii) 8.65%. As of December 31, 2022, the interest rate on the Term Loans w as 9.90 %. At our option, we may prepay all or any portion of the outstanding Term Loans at any time. Prepayments made on or prior to the third anniversary of the date of the Loan Agreement will be subject to a prepayment fee equal to 1.50 % of the principal amount being prepaid. In addition, we paid a $ 0.1 million facility charge upon closing and will pay additional facility charges in connection with any borrowing of the Tranche 2 Loan, Tranche 3 Loan or Tranche 4 Loan, in each case in the amount of 0.50 % of the amount of such tranche of loans. The Loan Agreement also provides for an end of term fee in an amount equal to the greater of approximately (i) $ 1.5 million (which is 6.05 % of the maximum amount of the first tranche of loans) or (ii) 6.05 % of the aggregate principal amount of loan advances actually made under the Loan Agreement, which fee is due and payable on the earliest to occur of (i) the Maturity Date, (ii) the date we prepay the outstanding loans in full, and (iii) the date that the secured obligations become due and payable. Our obligations under the Loan Agreement are secured by substantially all of our assets other than our intellectual property, but including proceeds from the sale, licensing or other disposition of our intellectual property. As part of the Loan Agreement, we are subject to certain negative covenants, which, among other things, prohibit us from selling, transferring, assigning, mortgaging, pledging, leasing, granting a security interest in or otherwise encumbering our intellectual property, subject to limited exceptions. The Loan Agreement also contains a minimum cash covenant, commencing on June 1, 2024, requiring us to hold cash in the United States and subject to a first-priority perfected security interest in favor of the Lenders in an amount greater than or equal to (x) 55.0% of the outstanding loan obligations if we have not received FDA approval for ziftomenib, or (y) 35.0% of the outstanding loan obligations if we have received FDA approval for ziftomenib, provided that neither (x) nor (y) will apply at any time our market capitalization is equal to or greater than $ 1,250.0 million. Additionally, the Loan Agreement contains minimum cash requirements in the event of (i) any Corporate Collaborations (as defined in the Loan Agreement) or (ii) any cash payment in respect of permitted convertible debt subject to the satisfaction of the Redemption Conditions (as defined in the Loan Agreement). In addition, the Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions. The Loan Agreement also contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, material adverse effects, breach of representations and warranties, cross-default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. Following an event of default and any applicable cure period, a default interest rate equal to the then-applicable interest rate plus 5.0 % may be applied to the outstanding principal balance, and the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Loan Agreement, in addition to other remedies available to them as our secured c reditors. We were in compliance with all covenants of the Loan Agreement as of December 31, 2022. In addition, in connection with the entry into the Loan Agreement, we issued warrants to certain of the Lenders, or collectively, the Warrants, to purchase up to 26,078 shares of our common stock at an exercise price of $ 14.38 per share, or the Warrant Shares. The Warrants may be exercised through the earlier of (i) the seventh anniversary of November 2, 2022 and (ii) the consummation of certain acquisition transactions involving us, as set forth in the Warrants. The number of Warrant Shares for which the Warrants are exercisable and the associated exercise price are subject to certain customary proportional adjustments for fundamental events, including stock splits and reverse stock splits, as set forth in the Warrants. If we make additional draws on the Tranche 2 Loan, Tranche 3 Loan or Tranche 4 Loan, upon the funding of such additional tranches, the Warrants shall become exercisable for an additional aggregate number of shares of our common stock equal to 1.50 % of each drawn amount divided by the exercise price of $ 14.38 per share. The initial tranche 1 borrowing of $ 10.0 million and the warrants issued upon closing to purchase 26,078 shares of our common stock are accounted for as freestanding debt and equity financial instruments, respectively, as they are legally detachable and separately exercisable. The additional borrowings available under the Tranche 1 Loan, Tranche 2 Loan, Tranche 3 Loan and Tranche 4 Loan plus the additional warrants to purchase shares of our common stock, which would be issued concurrently, are accounted for as a single freestanding financial instrument that are not assets or obligations of ours; this financial instrument meets the loan commitment derivative scope exception and will be accounted for when and if we borrow additional tranches in the future. In connection with the Loan Agreement, we recognized the initial 26,078 issued warrants at their relative fair value of approximately $ 0.3 million, and we incurred debt issuance costs of $ 0.6 million, which were recorded as debt discounts. The fair value of the warrants, debt issuance costs and end of term fee are being amortized and accreted into interest expense using the effective interest rate method over the term of the loan. The following table summarizes maturities of principal obligation payments under the term loan facility as of December 31, 2022, in thousands: Years Ending December 31, 2024 $ 464 2025 2,953 2026 3,263 2027 3,320 Total principal outstanding 10,000 Less: unamortized discounts ( 842 ) Long-term debt, net $ 9,158 In November 2018, we entered into a loan and security agreement with Silicon Valley Bank, or the SVB Loan Agreement, providing for up to $ 20.0 million in a series of term loans. Upon entering into the SVB Loan Agreement, we borrowed $ 7.5 million, or the SVB Term Loan. The SVB Term Loan had a scheduled maturity date of May 1, 2023 . In May 2021, we paid $ 6.6 million to repay all amounts owed under the SVB Term Loan, which included a final payment of $ 0.6 million, representing 7.75 % of the SVB Term Loan which was being accrued through interest expense using the effective interest method, and a prepayment fee of $ 30,000 . In accordance with ASC 470-50, Debt Modifications and Extinguishments, we accounted for the transaction as an extinguishment of debt. Accordingly, we recorded a loss of approximately $ 0.2 million, which is included in interest expense on the statements of operations and comprehensive loss for the year ended December 31, 2021.

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2022
License Agreements [Abstract]
License Agreements	7. License Agreements The University of Michigan License Agreement In December 2014 , we entered into a license agreement with the Regents of the University of Michigan, or the University of Michigan, which was amended in March 2015, July 2015, September 2016, February 2017, May 2017 and August 2017, under which we received certain license rights for a non-refundable upfront license, annual maintenance fees and payments upon achievement of certain development and sales-based milestones. The licensed asset consists of several compounds, including our development candidate ziftomenib. All future development, regulatory and commercial work on the asset will be completed fully and at our sole expense. The University of Michigan retains the right to use the asset for non-commercial research, internal and/or educational purposes, with the right to grant the same limited rights to other non-profit research institutions. The agreement will terminate upon the last-to-expire patent rights, or may be terminated by us at any time with 90 days written notice of termination or terminated by the University of Michigan upon a bankruptcy by us, payment failure by us that is not cured within 30 days or a material breach of the agreement by us that is not cured within 60 days . Janssen License Agreement In December 2014 , we entered into a license agreement with Janssen Pharmaceutica NV, or Janssen, which was amended in June 2016, under which we received certain intellectual property rights related to tipifarnib in all indications other than virology for a non-refundable $ 1.0 million upfront license fee and payments upon achievement of certain development and sales-based milestones. Tipifarnib is a clinical-stage compound and all ongoing development, regulatory and commercial work will be completed fully and at our sole expense. The agreement will terminate upon the last-to-expire patent rights or last-to-expire royalty term, or may be terminated by us with 180 days written notice of termination. Either party may terminate the agreement in the event of material breach of the agreement that is not cured within 45 days. Janssen may also terminate the agreement due to our lack of diligence that is not cured within a three-month period. Future Milestone Payments under License Agreements Collectively, all of our license agreements provide for specified development, regulatory and sales-based milestone payments up to a total of $ 80.2 million payable upon occurrence of each stated event, of which $ 0.5 million relates to the initiation of certain development activities, $ 28.9 million relates to the achievement of specified regulatory approvals for the first indication and up to $ 50.8 million relates to the achievement of specified levels of product sales. Additional payments will be due for each subsequent indication if specified regulatory approvals are achieved. As of December 31, 2022, we have paid milestone payments tot aling $ 0.2 million u nder the above-mentioned license agreements. Furthermore, if all the programs are successfully commercialized, we will be required to pay tiered royalties on annual net product sales ranging from the low single digits to the low teens, depending on the volume of sales and the respective agreement.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating Leases We currently have three operating leases for administrative and research and development office and lab space in San Diego, California and Boston, Massachusetts that expire between July 2024 and November 2025. Under the terms of the operating leases, we are required to pay our proportionate share of property taxes, insurance and normal maintenance costs. Two of our leases include renewal options for an additional five years , which were not included in the determination of the ROU asset or lease liability as the renewal was not reasonably certain at the inception of the lease. Our San Diego corporate headquarters lease and our San Diego lease for lab and office space provided for $ 1.0 million and $ 0.1 million, respectively, in reimbursements for allowable tenant improvements, which effectively reduced the total lease payments owed. Under the terms of our office lease in Boston, we are required to maintain a standby letter of credit of approximately $ 0.2 million during the term of the lease. Additionally, we had other operating leases including a sublease with a related party for office space in San Diego, California and a lease for office space in Cambridge, Massachusetts that ended in 2020, and a sublease for lab space in San Diego that ended in August 2021. Maturities of our lease liabilities as of December 31, 2022 are as follows, in thousands: Year Ending December 31, 2023 $ 2,375 2024 1,863 2025 929 Total lease payments 5,167 Less: imputed interest ( 301 ) Total operating lease liabilities $ 4,866 As of December 31, 2022 and 2021 , the weighted-average discount rate was 5.5 % for both periods, and the weighted-average remaining lease term was 2.3 years and 3.3 years, respectively. Total cash paid for amounts included in the measurement of operating lease liabilities, net of tenant improvement reimbursements, was $ 2.3 million, $ 2.1 million and $ 0.3 million for the years ended December 31, 2022, 2021 and 2020 , respectively. Operating lease ROU assets obtained in exchange for operating lease liabilities were zero , $ 1.0 million and $ 7.5 million for the years ended December 31, 2022, 2021 and 2020, respectively. Total operating lease expense was approximately $ 2.0 million, $ 2.0 million and $ 1.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. We had also entered into short-term operating leases that expired in 2020. Total rent expense for the years ended December 31, 2022, 2021 and 2020 was approximately $ 2.0 million in each year. Litigation From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our results of operations or financial position.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity In November 2022, we entered into a securities purchase agreement with Bristol-Myers Squibb Company, or BMS, pursuant to which BMS purchased an aggregate of 1,370,171 shares of our common stock at a purchase price of approximately $ 18.25 per share, for gross proceeds of approximately $ 25.0 million. In November 2022, in connection with the Loan Agreement, we issued warrants to certain of the Lenders to purchase up to 26,078 shares of our common stock at an exercise price of $ 14.38 per share, which are outstanding as of December 31, 2022. In February 2022, we terminated the Common Stock Sales Agreement with SVB Leerink LLC and Stifel, Nicolaus & Company, Incorporated and entered into a new Common Stock Sales Agreement with SVB Securities LLC, Credit Suisse Securities (USA) LLC and Cantor Fitzgerald & Co., or the ATM Facility, under which we may offer and sell, from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to $ 150.0 million. We have not sold any shares of our common stock under the ATM Facility. In December 2020, we completed a public offering in which we sold an aggregate of 9,326,500 shares of common stock at a price of $ 37.00 per share. Net proceeds from the public offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $ 324.1 million. In May 2020, we completed a public offering in which we sold an aggregate of 10,465,000 shares of common stock at a price of $ 13.75 per share. Net proceeds from the public offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $ 134.9 million. In connection with the loan and security agreement with Oxford Finance LLC and Silicon Valley Bank in 2016, we issued a warrant to Oxford Finance LLC to purchase up to 33,988 shares of our common stock at an exercise price of $ 3.31 per share, which remains outstanding as of December 31, 2022.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	10. Share-Based Compensation Equity Incentive Plan In March 2015, our board of directors adopted our Amended and Restated 2014 Equity Incentive Plan, or 2014 Plan, which provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, performance-based stock awards and other forms of equity compensation to our employees, consultants and members of our board of directors. The number of shares of our common stock available for future grant under the 2014 Plan will automatically increase on January 1 of each year through January 1, 2025 by 4 % of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. In September 2022, our board of directors approved the amendment of our 2014 Plan, subject to approval by our stockholders at the 2023 Annual Meeting of Stockholders, to, among other things, increase the aggregate number of shares of our common stock that may be issued pursuant to stock awards by 1,459,800 shares. On January 1, 2023, an automatic increase pursuant to the 2014 Plan occurred, resulting i n 2,732,559 additional shares of common stock available for future grants under the 2014 Plan. We issue shares of common stock upon the exercise of options and vesting of restricted stock unit awards with the source of those shares of common stock being newly issued shares. As of December 31, 2022 , 17,545,127 sh ares of common stock had been reserved for issuanc e, and 1,182,227 sh ares of common stock were available for grant under the 2014 Plan. Employee Stock Purchase Plan In March 2015, our board of directors adopted the 2015 Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase our common stock at a discount through payroll deductions during defined six-month offering periods. Eligible employees may elect to withhold up to 15 % of their base earnings to purchase shares of our common stock at a price equal to 85 % of the fair market value on the first day of the offering period or the purchase date, whichever is lower. The number of shares of our common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year through January 1, 2025 by the lesser of 1 % of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year and 2,000,000 shares of common stock, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. In December 2022, the compensation committee of our board of directors elected not to automatically increase the number of shares of our common stock reserved for issuance under the ESPP in 202 3. As of December 31, 2022, we have issued 176,992 s hares of common stock, and 727,433 s hares of common stock are reserved for future issuance under the ESPP. Share-based compensation expense related to the ESPP for the years ended December 31, 2022, 2021 and 2020 was $ 0.3 million , $ 0.3 million and $ 0.2 million, respectively. Stock Options and Restricted Stock Unit Awards Stock Options The exercise price of all stock options granted was equal to the fair market value of such stock on the date of grant. Stock options generally vest over a four-year period. The maximum contractual term for all stock options is ten years . The following is a summary of stock option activity for the year ended December 31, 2022, in thousands (except per share and years data): Number of Weighted Average Weighted Average Aggregate Outstanding as of December 31, 2021 6,951 $ 20.08 Granted 2,904 $ 14.51 Exercised ( 265 ) $ 14.16 Canceled ( 1,165 ) $ 21.69 Outstanding as of December 31, 2022 8,425 $ 18.12 7.6 $ 3,082 Vested and expected to vest as of December 31, 2022 8,425 $ 18.12 7.6 $ 3,082 Exercisable as of December 31, 2022 4,412 $ 17.84 6.7 $ 2,860 The aggregate intrinsic value in the above table is calculated as the difference between the closing price of our common stock as of December 31, 2022 of $ 12.41 per share and the exercise price of stock options that had strike prices below the closing price. The following summarizes certain information regarding stock options, in thousands (except per share data): Years Ended December 31, 2022 2021 2020 Cash received from options exercised $ 3,756 $ 3,809 $ 9,766 Intrinsic value of options exercised $ 701 $ 3,475 $ 13,348 Weighted-average grant date fair value per share $ 8.90 $ 17.84 $ 10.15 As of December 31, 2022, unrecognized estimated compensation expense related to stock options was $ 44.7 million, which is expected to be recognized over the weighted-average remaining requisite service period of approximately 2.5 years. Restricted Stock Unit Awards Restricted stock unit awards, or RSUs, are share awards that, upon vesting, will deliver to the holder shares of our common stock. We began issuing RSUs in 2021. The RSUs generally vest annually over four years . The following is a summary of RSU activity for the year ended December 31, 2022, in thousands (except per share and years data): Number of Weighted Average Weighted Average Aggregate Outstanding as of December 31, 2021 161 $ 32.80 Granted 746 $ 13.70 Released ( 40 ) $ 32.80 Canceled ( 99 ) $ 17.68 Outstanding as of December 31, 2022 768 $ 16.20 1.4 $ 9,541 Expected to vest as of December 31, 2022 768 $ 16.20 1.4 $ 9,541 As of December 31, 2022, unrecognized estimated compensation expense related to RSUs was $ 9.8 million, which is expected to be recognized over the weighted-average remaining requisite service period of approximately 2 .4 years. Share-Based Compensation Expense Total share-based compensation expense included on the statements of operations and comprehensive loss was comprised of the following, in thousands: Years Ended December 31, 2022 2021 2020 Research and development $ 10,373 $ 7,454 $ 3,960 General and administrative 15,945 16,125 8,847 Total share-based compensation expense $ 26,318 $ 23,579 $ 12,807 We estimated the fair value of stock options and ESPP stock purchase rights using the Black-Scholes model based on the date of grant with the following assumptions: Options ESPP Years Ended December 31, Years Ended December 31, 2022 2021 2020 2022 2021 2020 Expected term (in years) 5.45 — 6.57 5.50 — 6.08 5.50 — 6.08 0.50 0.50 0.50 Expected volatility 67.1 % — 71.9 % 72.0 % — 74.6 % 74.4 % — 76.1 % 61.0 % — 75.8 % 44.8 % — 61.8 % 55.3 % — 91.9 % Risk-free interest rate 1.6 % — 4.2 % 0.6 % — 1.3 % 0.4 % — 2.0 % 1.6 %— 4.6 % 0.0 %— 0.1 % 0.1 % — 0.9 % Expected dividend yield — — — — — — Expected term. The expected term of stock options represents the period that the stock options are expected to remain outstanding. Beginning in 2022, we determined our expected term assumption using our own historical exercise experience. In prior years, due to our limited historical exercise behavior, we determined the expected term assumption using the simplified method. The expected term of the ESPP stock purchase rights is six months, which represents the length of each purchase period. Expected volatility. Beginning in 2022, expected volatility for stock options was calculated based on our historical volatility. In prior years, due to our limited trading history, expected volatility was based, in part, on our historical volatility and the historical volatility of comparable publicly-traded companies. Expected volatility for the ESPP stock purchase rights is based on our historical volatility. Risk-free interest rate. The risk-free interest rates are based on the U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. Expected dividend yield. The expected dividend yield of zero reflects that we have not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions Our president and chief executive officer is also the sole managing member and a significant stockholder of Araxes Pharma LLC, or Araxes. The following is a summary of related party transactions for the years ended December 31, 2022, 2021 and 2020: • Facility Sublease We subleased office space in San Diego, California from Araxes between June 2017 and June 2020. The monthly rent expense was between $ 16,000 to $ 24,000 per month during the sublease term. Rent expense, including operating costs, related to the sublease for the year ended December 31, 2020 was approximately $ 0.2 million. • Management Fees We have a management services agreement with Araxes pursuant to which Araxes pays us monthly fees for management services calculated based on costs incurred by us in the provision of services to Araxes, plus a reasonable mark-up. For the years ended December 31, 2022, 2021 and 2020, we recorded management fee income of approximate ly $ 0.1 million each year, which is included in interest and other income, net on the statements of operations and comprehensive loss. In addition, the agreement allows for Araxes to reimburse us an amount equal to the number of full-time equivalents, or FTE, performing research and development services for Araxes, plus actual expenses as reasonably incurred. For the years ended December 31, 2022 , 2021 and 2020, we did no t record any reimbursements for research and development expenses provided to Araxes. • Services Agreements We have a services agreement with Wellspring Biosciences, Inc., or Wellspring, a wholly-owned subsidiary of Araxes, pursuant to which we pay Wellspring for research and development services provided to us in an amount equal to the number of FTE’s performing the services, at an annual FTE rate of $ 400,000 , plus actual expenses as reasonably incurred. For the years ended December 31, 2022 and 2021, we did not recognize any expense under this service agreement. For the year ended December 31, 2020 , we recognized approximately $ 0.1 million from research and development services provided to us under this agreement as research and development expense on the statements of operations and comprehensive loss. We had a services agreement with ALG Partners, Inc., or ALG Partners, a recruiting and temporary staffing agency. Our chief operating officer is an immediate family member of the president of ALG Partners. There were no related party expenses with ALG Partners for the years ended December 31, 2022 and 2021. For the year ended December 31, 2020, expenses recognized as related party transactions with ALG Partners were approximately $ 0.1 million.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2022
Postemployment Benefits [Abstract]
Employee Benefit Plan	12. Employee Benefit Plan We have a defined contribution 401(k) plan for all employees. Under the terms of the plan, employees may make voluntary contributions as a percentage or defined amount of compensation. We provided a safe harbor contribution of 4.0 % of the employee’s compensation in 2022 and 2021 and 3.0 % in 2020 and prior years, not to exceed eligible limits. For the years ended December 31, 2022, 2021 and 2020, we incurred approximately $ 1.2 million, $ 1.0 million and $ 0.6 million, respectively, in expenses related to the safe harbor contribution.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes For the years ended December 31, 2022, 2021 and 2020 , we did no t record a provision for income taxes due to a full valuation against our deferred taxes. Our effective income tax rate differs from the statutory federal rate of 21 % for the years ended December 31, 2022, 2021 and 2020, due to the following, in thousands: Years Ended December 31, 2022 2021 2020 Income taxes at statutory federal rate $ ( 28,526 ) $ ( 27,398 ) $ ( 18,821 ) State income tax, net of federal benefit ( 9,721 ) ( 9,758 ) ( 7,684 ) Research and development tax credits ( 6,970 ) ( 5,850 ) ( 3,169 ) Share-based compensation 3,998 2,819 ( 304 ) Other ( 69 ) ( 496 ) ( 120 ) Valuation allowance 41,288 40,683 30,098 Income tax expense $ — $ — $ — Significant components of our deferred tax assets and liabilities are shown below, in thousands: December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 125,986 $ 111,238 Research and development tax credit carryforwards 20,876 13,794 Section 174 capitalization 16,684 — Share-based compensation 6,599 4,842 Accruals 2,713 2,096 Other comprehensive income 2,360 526 Operating lease liabilities 1,430 2,021 Other 1,018 562 Total gross deferred tax assets 177,666 135,079 Less: valuation allowance ( 176,328 ) ( 133,206 ) Net deferred tax assets 1,338 1,873 Deferred tax liabilities: Operating lease right-of-use assets ( 1,129 ) ( 1,638 ) Other ( 209 ) ( 235 ) Total gross deferred tax liabilities ( 1,338 ) ( 1,873 ) Net deferred tax assets $ — $ — As of December 31, 2022 , we had federal net operating loss, or NOL, carryforwards of $ 412.6 million, of which $ 337.2 million can be carried forward indefinitely. The remaining federal net operating loss carryforwards of $ 75.4 million will begin to expire in 2034 , unless previously utilized. In addition, as of December 31, 2022, we had state loss carryforwards of $ 572.0 million which will begin to expire in 2030 , unless previously utilized. We also have federal and state research and development credit carryforwards of $ 22.6 million and $ 5.4 million, respectively, as of December 31, 2022. The federal research and development credits will begin to expire in 2034 , unless previously utilized. Of the state research and development credits, $ 3.0 million will carryforward indefinitely and approximately $ 2.4 million will begin to expire in 2031 , unless previously utilized . We file tax returns as prescribed by the tax laws of the jurisdictions in which we operate. Our tax years since inception are subject to examination by the federal and state jurisdictions due to the carryforward of unutilized net operating losses and research and development credits. We have not been, nor are we currently, under examination by the federal or any state tax authority. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of the evidence, including our limited existence and losses since inception, management has determined that it is more likely than not that the deferred tax assets will not be realized and therefore has recorded a full valuation allowance against the deferred taxes. The valuation allowance increased by $ 43.1 m illion from December 31, 2021. Pursuant to Sections 382 and 383 of the Internal Revenue Code, or IRC, annual use of our NOL or research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. We previously completed a study to assess whether an ownership change, as defined by IRC Section 382, had occurred from our formation through March 31, 2016. Based upon this study, we determined that an ownership change occurred but concluded the annual utilization limitation would be sufficient to utilize our pre-ownership change NOLs and research and development credits prior to expiration. We completed additional studies and concluded no further ownership changes occurred through December 31, 2021. We are currently in the process of completing a study for 2022, however, we do not expect any material limitations to the utilization of NOLs or research and development credits. Future ownership changes may limit our ability to utilize remaining tax attributes. Any carryforwards that will expire prior to utilization as a result of such additional limitations will be removed from deferred tax assets, with a corresponding reduction of the valuation allowance. In accordance with authoritative guidance, the impact of an uncertain income tax position is recognized at the largest amount that is “more likely than not” to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. The following table summarizes the activity related to our unrecognized tax benefits, in thousands: December 31, 2022 2021 2020 Gross unrecognized tax benefits at the beginning of the year $ 4,402 $ 2,978 $ 1,741 Increases related to prior year tax positions 67 — — Increases from tax positions taken in the current year 2,016 1,424 1,237 Gross unrecognized tax benefits at the end of the year $ 6,485 $ 4,402 $ 2,978 Our practice is to recognize interest and penalties related to income tax matters in income tax expense. There was no accrued interest or penalties included on the balance sheets as of December 31, 2022 and 2021, and we have not recognized interest and penalties on the statements of operations and comprehensive loss for the years ended December 31, 2022, 2021 or 2020. We do not expect that there will be a significant change in the unrecognized tax benefits over the next 12 months. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact our effective tax rate.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Reclassifications	Reclassifications Certain prior period balances have been reclassified to conform to the current period presentation.
Use of Estimates	Use of Estimates Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. We operate in a single industry segment which is the discovery and development of precision medicines for the treatment of cancer. Our chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment in the United States.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of checking, money market and highly liquid investments that are readily convertible to cash and that have an original maturity of three months or less from date of purchase. The carrying amounts approximate fair value due to the short maturities of these instruments.
Restricted Cash	Restricted Cash Under the terms of an office lease entered into in March 2020, we are required to maintain a standby letter of credit during the term of the lease. As of December 31, 2022 , restricted cash of $ 0.2 million was pledged as collateral for the letter of credit. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the balance sheets that sum to the total of the amounts shown on the statements of cash flows, in thousands: December 31, 2022 2021 2020 Cash and cash equivalents $ 51,802 $ 90,672 $ 325,493 Restricted cash 210 210 210 Total $ 52,012 $ 90,882 $ 325,703
Short-Term Investments	Short-Term Investments Short-term investments are marketable securities with maturities greater than three months from date of purchase that are specifically identified to fund current operations. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund our operations, as necessary. The cost of short-term investments is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in interest income. Dividend and interest income is recognized as interest income on the statements of operations and comprehensive loss when earned. Short-term investments are classified as available-for-sale securities and carried at fair value with unrealized gains and non-credit related losses recorded in other comprehensive loss and included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities are determined on a specific identification basis and included in interest and other income, net on the statements of operations and comprehensive loss.
Allowance for Credit Losses on Available-for-Sale Debt Securities	Allowance for Credit Losses For available-for-sale securities in an unrealized loss position, we first assess whether we intend to sell, or if it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive loss on the statements of operations and comprehensive loss. We elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of our available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded in prepaid expenses and other current assets on our balance sheets. Our accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and placing investments with maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: • Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; • Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Computer software and equipment are depreciated over their estimated useful lives of three to five years . Laboratory equipment is depreciated over its estimated useful life of five years . Furniture and fixtures are depreciated over their estimated useful lives of five years . Leasehold improvements are depreciated over the lesser of the term of the related lease or the useful life of the asset.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. For the years ended December 31, 2022, 2021 and 2020 , there were no impairments of the value of long-lived assets.
Leases	Leases We determine if an arrangement is a lease or contains lease components at inception. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. For operating leases with an initial term greater than 12 months, we recognize operating lease right-of-use, or ROU, assets and operating lease liabilities based on the present value of lease payments over the lease term at commencement date. Operating lease ROU assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate when we are reasonably certain that the options will be exercised. We do not separate lease components from non-lease components. For our operating leases, we generally cannot determine the interest rate implicit in the lease, in which case we use our incremental borrowing rate as the discount rate for the lease. We estimate our incremental borrowing rate for our operating leases based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. If a lease is modified, the modified contract is evaluated to determine whether it is or contains a lease. If a lease continues to exist, the lease modification is determined to be a separate contract when the modification grants the lessee an additional ROU that is not included in the original lease and the lease payments increase commensurate with the standalone price for the additional ROU. A lease modification that results in a separate contract will be accounted for in the same manner as a new lease. For a modification that is not a separate contract, we reassess the lease classification using the modified terms and conditions and the facts and circumstances as of the effective date of the modification and recognize the amount of the remeasurement of the lease liability for the modified lease as an adjustment to the corresponding operating lease ROU asset.
Research and Development Expenses	Research and Development Expenses Research and development expenses consist of costs associated with our research and development activities including salaries, benefits, share-based compensation and other personnel costs, clinical trial costs, manufacturing costs for non-commercial products, fees paid to external service providers and consultants, facilities costs and supplies, equipment and materials used in clinical and preclinical studies and research and development. All such costs are charged to research and development expense as incurred when these expenditures have no alternative future uses. We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed. Payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses in other research and development projects or otherwise, and therefore have no separate economic value, are expensed as research and development costs at the time such costs are incurred. As of December 31, 2022 , we had no in-licensed technologies that have alternative future uses in research and development projects or otherwise.
Clinical Trial Costs and Accruals	Clinical Trial Costs and Accruals A significant portion of our clinical trial costs relate to contracts with contract research organizations, or CROs. The financial terms of our CRO contracts may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs concerning monthly expenses as well as reimbursement for pass through costs. We are also required to estimate certain of our expenses resulting from our obligations under our CRO contracts. Accordingly, our clinical trial expense accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. If the contracted amounts are modified, for instance, as a result of changes in the clinical trial protocol or scope of work to be performed, we modify our accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Historically, we have had no material changes in clinical trial expense that had a material impact on our results of operations or financial position.
Patent Costs	Patent Costs We expense all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications, and such costs are included in general and administrative expenses on the statements of operations and comprehensive loss.
Share-Based Compensation	Share-Based Compensation Our share-based awards are measured at fair value on the date of grant based upon the estimated fair value of common stock. The fair value of awards expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award less actual forfeitures. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model, or Black-Scholes model, that requires the use of assumptions including volatility, expected term, risk-free rate and the fair value of the underlying common stock. We estimate the fair value of restricted stock units granted based on the closing market price of our common stock on the date of grant. Actual forfeitures are applied as they occur, and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.
Income Taxes	Income Taxes Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. For uncertain tax positions that meet “a more likely than not” threshold, we recognize the benefit of uncertain tax positions in the financial statements.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as the change in equity during the period from transactions and other events and non-owner sources. For the periods presented, accumulated other comprehensive loss consisted of unrealized gains and losses on marketable securities and foreign currency.
Net Loss per Share	Net Loss per Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock method. As we have reported net loss for the years ended December 31, 2022, 2021 and 2020, dilutive net loss per common share is the same as basic net loss per common share for those periods. Common stock equivalents outstanding are comprised of stock options, restricted stock units, warrants and employee stock purchase plan rights and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Common stock equivalents outstanding as of December 31, 2022, 2021 and 2020 totaling approximately 9,266,000 , 7,156,000 and 5,059,000 , respectively, were excluded from the computation of dilutive weighted-average shares outstanding because their effect would be anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. We have evaluated recently issued accounting pronouncements and, based on our preliminary assessment, we do not believe any will have a material impact on our financial statements or related footnote disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the balance sheets that sum to the total of the amounts shown on the statements of cash flows, in thousands: December 31, 2022 2021 2020 Cash and cash equivalents $ 51,802 $ 90,672 $ 325,493 Restricted cash 210 210 210 Total $ 52,012 $ 90,882 $ 325,703

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Investments Measured at Fair Value on Recurring Basis	The following tables summarize, by major security type, our short-term investments that are measured at fair value on a recurring basis, in thousands: December 31, 2022 Maturities Amortized Unrealized Unrealized Estimated Fair Value Cash equivalents: Money market funds 1 or less $ 37,878 $ — $ — $ 37,878 U.S. Agency bonds 1 or less 9,956 — — 9,956 Total cash equivalents 47,834 — — 47,834 Short-term investments: U.S. Treasury securities 2 or less 183,051 16 ( 3,018 ) 180,049 Corporate debt securities 2 or less 115,763 — ( 3,931 ) 111,832 Commercial paper 1 or less 52,941 — — 52,941 Non-U.S. government and supranational debt securities 2 or less 26,268 — ( 950 ) 25,318 U.S. Agency bonds 1 or less 16,192 11 ( 160 ) 16,043 Total short-term investments 394,215 27 ( 8,059 ) 386,183 Total $ 442,049 $ 27 $ ( 8,059 ) $ 434,017 December 31, 2021 Maturities Amortized Unrealized Unrealized Estimated Fair Value Cash equivalents: Money market funds 1 or less $ 79,895 $ — $ — $ 79,895 Short-term investments: U.S. Treasury securities 3 or less 135,452 — ( 619 ) 134,833 Corporate debt securities 3 or less 208,064 — ( 892 ) 207,172 Commercial paper 1 or less 53,439 — — 53,439 Non-U.S. government and supranational debt securities 3 or less 23,122 — ( 214 ) 22,908 U.S. Agency bonds 2 or less 8,994 — ( 58 ) 8,936 Total short-term investments 429,071 — ( 1,783 ) 427,288 Total $ 508,966 $ — $ ( 1,783 ) $ 507,183

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule Of Fair Value Measurements, By Major Security Type	The following tables summarize, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy, in thousands: December 31, 2022 Total Level 1 Level 2 Cash equivalents: Money market funds $ 37,878 $ 37,878 $ — U.S. Agency bonds 9,956 — 9,956 Total cash equivalents 47,834 37,878 9,956 Short-term investments: U.S. Treasury securities 180,049 180,049 — Corporate debt securities 111,832 — 111,832 Commercial paper 52,941 — 52,941 Non-U.S. government and supranational debt securities 25,318 — 25,318 U.S. Agency bonds 16,043 — 16,043 Total short-term investments 386,183 180,049 206,134 Total $ 434,017 $ 217,927 $ 216,090 December 31, 2021 Total Level 1 Level 2 Cash equivalents: Money market funds $ 79,895 $ 79,895 $ — Short-term investments: U.S. Treasury securities 134,833 134,833 — Corporate debt securities 207,172 — 207,172 Commercial paper 53,439 — 53,439 Non-U.S. government and supranational debt securities 22,908 — 22,908 U.S. Agency bonds 8,936 — 8,936 Total short-term investments 427,288 134,833 292,455 Total $ 507,183 $ 214,728 $ 292,455

Balance Sheet Detail (Tables)

Balance Sheet Detail (Tables)	12 Months Ended
	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following, in thousands: December 31, 2022 2021 Laboratory and computer equipment $ 1,568 $ 953 Leasehold improvements 1,543 1,532 Furniture and fixtures 1,032 1,032 Property and equipment, gross 4,143 3,517 Less: accumulated depreciation ( 1,603 ) ( 844 ) Property and equipment, net $ 2,540 $ 2,673
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following, in thousands: December 31, 2022 2021 Accounts payable $ 1,533 $ 3,236 Accrued clinical trial research and development expenses 2,440 2,619 Accrued other research and development expenses 5,030 5,341 Accrued compensation and benefits 10,300 7,923 Other accrued expenses 2,436 1,073 Total accounts payable and accrued expenses $ 21,739 $ 20,192

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Summary of Maturities of Principal Obligation Under Term Loan Facility	The following table summarizes maturities of principal obligation payments under the term loan facility as of December 31, 2022, in thousands: Years Ending December 31, 2024 $ 464 2025 2,953 2026 3,263 2027 3,320 Total principal outstanding 10,000 Less: unamortized discounts ( 842 ) Long-term debt, net $ 9,158

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Maturities of Lease Liabilities	Maturities of our lease liabilities as of December 31, 2022 are as follows, in thousands: Year Ending December 31, 2023 $ 2,375 2024 1,863 2025 929 Total lease payments 5,167 Less: imputed interest ( 301 ) Total operating lease liabilities $ 4,866

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activities	The following is a summary of stock option activity for the year ended December 31, 2022, in thousands (except per share and years data): Number of Weighted Average Weighted Average Aggregate Outstanding as of December 31, 2021 6,951 $ 20.08 Granted 2,904 $ 14.51 Exercised ( 265 ) $ 14.16 Canceled ( 1,165 ) $ 21.69 Outstanding as of December 31, 2022 8,425 $ 18.12 7.6 $ 3,082 Vested and expected to vest as of December 31, 2022 8,425 $ 18.12 7.6 $ 3,082 Exercisable as of December 31, 2022 4,412 $ 17.84 6.7 $ 2,860
Summary of Information Regarding Stock Options	The following summarizes certain information regarding stock options, in thousands (except per share data): Years Ended December 31, 2022 2021 2020 Cash received from options exercised $ 3,756 $ 3,809 $ 9,766 Intrinsic value of options exercised $ 701 $ 3,475 $ 13,348 Weighted-average grant date fair value per share $ 8.90 $ 17.84 $ 10.15
Summary of RSU Activity	The following is a summary of RSU activity for the year ended December 31, 2022, in thousands (except per share and years data): Number of Weighted Average Weighted Average Aggregate Outstanding as of December 31, 2021 161 $ 32.80 Granted 746 $ 13.70 Released ( 40 ) $ 32.80 Canceled ( 99 ) $ 17.68 Outstanding as of December 31, 2022 768 $ 16.20 1.4 $ 9,541 Expected to vest as of December 31, 2022 768 $ 16.20 1.4 $ 9,541
Summary of Share-based Compensation Expense	Total share-based compensation expense included on the statements of operations and comprehensive loss was comprised of the following, in thousands: Years Ended December 31, 2022 2021 2020 Research and development $ 10,373 $ 7,454 $ 3,960 General and administrative 15,945 16,125 8,847 Total share-based compensation expense $ 26,318 $ 23,579 $ 12,807
Summary of Estimate Fair Value of Stock Options and ESPP Stock Purchase Rights Using Black-Scholes Model	We estimated the fair value of stock options and ESPP stock purchase rights using the Black-Scholes model based on the date of grant with the following assumptions: Options ESPP Years Ended December 31, Years Ended December 31, 2022 2021 2020 2022 2021 2020 Expected term (in years) 5.45 — 6.57 5.50 — 6.08 5.50 — 6.08 0.50 0.50 0.50 Expected volatility 67.1 % — 71.9 % 72.0 % — 74.6 % 74.4 % — 76.1 % 61.0 % — 75.8 % 44.8 % — 61.8 % 55.3 % — 91.9 % Risk-free interest rate 1.6 % — 4.2 % 0.6 % — 1.3 % 0.4 % — 2.0 % 1.6 %— 4.6 % 0.0 %— 0.1 % 0.1 % — 0.9 % Expected dividend yield — — — — — —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Our effective income tax rate differs from the statutory federal rate of 21 % for the years ended December 31, 2022, 2021 and 2020, due to the following, in thousands: Years Ended December 31, 2022 2021 2020 Income taxes at statutory federal rate $ ( 28,526 ) $ ( 27,398 ) $ ( 18,821 ) State income tax, net of federal benefit ( 9,721 ) ( 9,758 ) ( 7,684 ) Research and development tax credits ( 6,970 ) ( 5,850 ) ( 3,169 ) Share-based compensation 3,998 2,819 ( 304 ) Other ( 69 ) ( 496 ) ( 120 ) Valuation allowance 41,288 40,683 30,098 Income tax expense $ — $ — $ —
Components of Deferred Tax Assets and Liabilities	Significant components of our deferred tax assets and liabilities are shown below, in thousands: December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 125,986 $ 111,238 Research and development tax credit carryforwards 20,876 13,794 Section 174 capitalization 16,684 — Share-based compensation 6,599 4,842 Accruals 2,713 2,096 Other comprehensive income 2,360 526 Operating lease liabilities 1,430 2,021 Other 1,018 562 Total gross deferred tax assets 177,666 135,079 Less: valuation allowance ( 176,328 ) ( 133,206 ) Net deferred tax assets 1,338 1,873 Deferred tax liabilities: Operating lease right-of-use assets ( 1,129 ) ( 1,638 ) Other ( 209 ) ( 235 ) Total gross deferred tax liabilities ( 1,338 ) ( 1,873 ) Net deferred tax assets $ — $ —
Schedule of Activity Related to Unrecognized Tax Benefits	The following table summarizes the activity related to our unrecognized tax benefits, in thousands: December 31, 2022 2021 2020 Gross unrecognized tax benefits at the beginning of the year $ 4,402 $ 2,978 $ 1,741 Increases related to prior year tax positions 67 — — Increases from tax positions taken in the current year 2,016 1,424 1,237 Gross unrecognized tax benefits at the end of the year $ 6,485 $ 4,402 $ 2,978

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 USD ($) Segment shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Summary Of Significant Accounting Policies [Line Items]
Number of operating segments | Segment	1
Restricted cash pledged as collateral	$ 210,000	$ 210,000	$ 210,000
Impairment losses on long-lived assets	$ 0	$ 0	$ 0
Operating lease, existence of option to extend	true
Operating lease, existence of option to extend description	Lease terms may include options to extend or terminate when we are reasonably certain that the options will be exercised.
Operating lease, existence of option to terminate	true
Operating lease, option to terminate description	Lease terms may include options to extend or terminate when we are reasonably certain that the options will be exercised.
Total potentially dilutive securities | shares	9,266,000	7,156,000	5,059,000
Computer Software and Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful life	3 years
Computer Software and Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful life	5 years
Laboratory Equipment
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful life	5 years
Furniture and Fixtures
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful life	5 years
Collateral Pledged
Summary Of Significant Accounting Policies [Line Items]
Restricted cash pledged as collateral	$ 200,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 51,802	$ 90,672	$ 325,493
Restricted cash	210	210	210
Total	$ 52,012	$ 90,882	$ 325,703	$ 26,135

Investments - Investments Measu

Investments - Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Estimated Fair Value	$ 386,183	$ 427,288
Fair Value Measurements on Recurring Basis
Schedule Of Available For Sale Securities [Line Items]
Cash equivalents, Amortized Cost	47,834
Cash equivalents, Estimated Fair Value	47,834
Short-term investments, Amortized Cost	394,215	429,071
Short-term investments, Unrealized Gains	27
Short-term investments, Unrealized Losses	(8,059)	(1,783)
Short-term investments, Estimated Fair Value	386,183	427,288
Cash equivalents and Short-term investments, Amortized Cost	442,049	508,966
Cash equivalents and Short-term investments, Unrealized Losses	(8,059)	(1,783)
Cash equivalents and Short-term investments, Estimated Fair Value	$ 434,017	$ 507,183
Fair Value Measurements on Recurring Basis | Money Market Funds
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	1 or less	1 or less
Cash equivalents, Amortized Cost	$ 37,878	$ 79,895
Cash equivalents, Estimated Fair Value	37,878	79,895
Fair Value Measurements on Recurring Basis | U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	183,051	135,452
Short-term investments, Unrealized Gains	16
Short-term investments, Unrealized Losses	(3,018)	(619)
Short-term investments, Estimated Fair Value	$ 180,049	$ 134,833
Fair Value Measurements on Recurring Basis | U.S. Treasury Securities | Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	2 years	3 years
Fair Value Measurements on Recurring Basis | Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	$ 115,763	$ 208,064
Short-term investments, Unrealized Losses	(3,931)	(892)
Short-term investments, Estimated Fair Value	$ 111,832	$ 207,172
Fair Value Measurements on Recurring Basis | Corporate Debt Securities | Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	2 years	3 years
Fair Value Measurements on Recurring Basis | Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	$ 52,941	$ 53,439
Short-term investments, Estimated Fair Value	$ 52,941	$ 53,439
Fair Value Measurements on Recurring Basis | Commercial Paper | Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	1 year	1 year
Fair Value Measurements on Recurring Basis | Non U S Government And Supranational Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Short-term investments, Amortized Cost	$ 26,268	$ 23,122
Short-term investments, Unrealized Losses	(950)	(214)
Short-term investments, Estimated Fair Value	$ 25,318	$ 22,908
Fair Value Measurements on Recurring Basis | Non U S Government And Supranational Debt Securities | Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	2 years	3 years
Fair Value Measurements on Recurring Basis | U.S. Agency Bonds
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	1
Cash equivalents, Amortized Cost	$ 9,956
Cash equivalents, Estimated Fair Value	9,956
Short-term investments, Amortized Cost	16,192	$ 8,994
Short-term investments, Unrealized Gains	11
Short-term investments, Unrealized Losses	(160)	(58)
Short-term investments, Estimated Fair Value	$ 16,043	$ 8,936
Fair Value Measurements on Recurring Basis | U.S. Agency Bonds | Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturities (years)	1 year	2 years

Investments - Additional Inform

Investments - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 USD ($) Security	Dec. 31, 2021 USD ($) Security
Investments, All Other Investments [Abstract]
Short-term investments with maturities less than one year	$ 274,300,000	$ 246,900,000
Short-term investments with maturities between one to three years	$ 111,900,000	$ 180,400,000
Short-term investments maturities, description	As of December 31, 2022 and 2021, short-term investments of $274.3 million and $246.9 million, respectively, had maturities less than one year, and short-term investments of $111.9 million and $180.4 million, respectively, had maturities between one to three years.
Number of available-for-sale securities | Security	34	36
Available for sale securities gross unrealized loss positions	$ 290,000,000	$ 373,900,000
Available for sale securities gross unrealized loss positions greater than 12 months	172,400,000	0
Allowance for credit losses	0	0
Accrued interest receivable on available-for-sale securities	$ 900,000	$ 1,400,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule Of Fair Value Measurements, By Major Security Type (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	$ 386,183	$ 427,288
Fair Value Measurements on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	47,834
Short-term investments	386,183	427,288
Cash equivalents and short-term investments	434,017	507,183
Fair Value Measurements on Recurring Basis | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	37,878
Short-term investments	180,049	134,833
Cash equivalents and short-term investments	217,927	214,728
Fair Value Measurements on Recurring Basis | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	9,956
Short-term investments	206,134	292,455
Cash equivalents and short-term investments	216,090	292,455
Fair Value Measurements on Recurring Basis | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	37,878	79,895
Fair Value Measurements on Recurring Basis | Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	37,878	79,895
Fair Value Measurements on Recurring Basis | U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	180,049	134,833
Fair Value Measurements on Recurring Basis | U.S. Treasury Securities | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	180,049	134,833
Fair Value Measurements on Recurring Basis | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	111,832	207,172
Fair Value Measurements on Recurring Basis | Corporate Debt Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	111,832	207,172
Fair Value Measurements on Recurring Basis | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	52,941	53,439
Fair Value Measurements on Recurring Basis | Commercial Paper | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	52,941	53,439
Fair Value Measurements on Recurring Basis | Non U S Government And Supranational Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	25,318	22,908
Fair Value Measurements on Recurring Basis | Non U S Government And Supranational Debt Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	25,318	22,908
Fair Value Measurements on Recurring Basis | U S Agency Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	9,956
Short-term investments	16,043	8,936
Fair Value Measurements on Recurring Basis | U S Agency Bonds | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	9,956
Short-term investments	$ 16,043	$ 8,936

Balance Sheet Detail - Summary

Balance Sheet Detail - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 4,143	$ 3,517
Less: accumulated depreciation	(1,603)	(844)
Property and equipment, net	2,540	2,673
Laboratory and Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,568	953
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,543	1,532
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,032	$ 1,032

Balance Sheet Detail - Addition

Balance Sheet Detail - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Depreciation expense	$ 759	$ 558	$ 194

Balance Sheet Detail - Summar_2

Balance Sheet Detail - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Accounts payable	$ 1,533	$ 3,236
Accrued clinical trial research and development expenses	2,440	2,619
Accrued other research and development expenses	5,030	5,341
Accrued compensation and benefits	10,300	7,923
Other accrued expenses	2,436	1,073
Total accounts payable and accrued expenses	$ 21,739	$ 20,192

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
	Nov. 02, 2022	May 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Nov. 01, 2018
Debt Instrument [Line Items]
Principal amount outstanding on loan			$ 10,000,000
Loan agreement, description			The Loan Agreement also contains a minimum cash covenant, commencing on June 1, 2024, requiring us to hold cash in the United States and subject to a first-priority perfected security interest in favor of the Lenders in an amount greater than or equal to (x) 55.0% of the outstanding loan obligations if we have not received FDA approval for ziftomenib, or (y) 35.0% of the outstanding loan obligations if we have received FDA approval for ziftomenib, provided that neither (x) nor (y) will apply at any time our market capitalization is equal to or greater than $1,250.0 million.
Event of default interest rate increase	5%
Prepayment fee related to extinguishment of debt				$ 611,000
Loss from extinguishment of debt				$ 212,000
Minimum
Debt Instrument [Line Items]
Cash covenant market capitalization requirement	$ 1,250,000,000
Loan and Security Agreement
Debt Instrument [Line Items]
Warrant issued	26,078
Warrants exercisable exercise price	$ 14.38		$ 14.38
Fair value associated with equity classified warrants	$ 300,000
Debt issuance cost	600,000
Tranche 1 draw | Loan and Security Agreement
Debt Instrument [Line Items]
Principal amount outstanding on loan	$ 10,000,000
Warrant issued	26,078
Tranche 1 Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity under term loans	$ 25,000,000
Remaining borrowing capacity under term loans	$ 15,000,000
Tranche 1 availability end date	Sep. 15, 2023
Tranche 2 Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity under term loans	$ 35,000,000
Tranche 3 Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity under term loans	40,000,000
Tranche 4 Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity under term loans	$ 25,000,000
Term Loan | Loan and Security Agreement
Debt Instrument [Line Items]
Principal and interest payments start date			Nov. 01, 2024
Term loan facility per annum interest rate terms			The per annum interest rate for the Term Loans is the greater of (i) the prime rate as reported in The Wall Street Journal minus 6.25% plus 8.65% and (ii) 8.65%.
Percentage of prepayment fee to be paid due to early payment	1.50%
Commitment fees	$ 100,000
Percentage of facility charge	0.50%
Final payment	$ 1,500,000
Term loan facility maturity date			Nov. 02, 2027
Term loan current interest rate			9.90%
Term Loan | Loan and Security Agreement | Additional Interest Due as Final Payment
Debt Instrument [Line Items]
Final payment percentage	6.05%
Term Loan | Loan and Security Agreement | Maximum
Debt Instrument [Line Items]
Final payment percentage	6.05%
Interest Only Milestone 1 Conditions | Loan and Security Agreement
Debt Instrument [Line Items]
Repayment of term loan facility start date			May 01, 2025
Interest Only Milestone 2 Conditions | Loan and Security Agreement
Debt Instrument [Line Items]
Repayment of term loan facility start date			Nov. 01, 2025
Approval Milestone | Loan and Security Agreement
Debt Instrument [Line Items]
Repayment of term loan facility start date			Nov. 01, 2026
Additional Tranche | Loan and Security Agreement
Debt Instrument [Line Items]
Warrants exercisable exercise price	$ 14.38
Percentage of additional warrant	1.50%
Silicon Valley Bank | Term Loan
Debt Instrument [Line Items]
Maximum borrowing capacity under term loans					$ 20,000,000
Principal amount outstanding on loan					$ 7,500,000
Final payment		$ 600,000
Description of term loan payment terms			The SVB Term Loan had a scheduled maturity date of May 1, 2023.
Term loan facility maturity date				May 01, 2023
Repayments Of Debt		$ 6,600,000
Final payment percentage		7.75%
Prepayment fee related to extinguishment of debt		$ 30,000
Loss from extinguishment of debt				$ 200,000

Long-Term Debt - Summary of Mat

Long-Term Debt - Summary of Maturities of Principal Obligation Under Term Loan Facility (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2024	$ 464
2025	2,953
2026	3,263
2027	3,320
Total future minimum payments	10,000
Less: unamortized discounts	(842)
Long-term debt, net	$ 9,158

License Agreements - Additional

License Agreements - Additional Information (Detail) - USD ($) $ in Millions			12 Months Ended
	Dec. 22, 2014	Dec. 18, 2014	Dec. 31, 2022
License Agreements [Line Items]
Total future milestone payments under license agreements with non-related parties	$ 80.2
Milestone paid to date			$ 0.2
The University of Michigan License Agreement
License Agreements [Line Items]
License agreement date	Dec. 22, 2014
Agreement termination written notice	90 days
Agreement termination notice period in event of material breach	60 days
Agreement termination period due to payment failure	30 days
Janssen License Agreement
License Agreements [Line Items]
License agreement date		Dec. 22, 2014
Agreement termination written notice		180 days
Agreement termination notice period in event of material breach		45 days
Janssen License Agreement | Up front Payment Arrangement
License Agreements [Line Items]
Upfront license fee		$ 1
Initiation of Certain Development Activities
License Agreements [Line Items]
Total future milestone payments under license agreements with non-related parties	$ 0.5
Specified Regulatory Approvals
License Agreements [Line Items]
Total future milestone payments under license agreements with non-related parties	28.9
Specified Levels of Product Sales
License Agreements [Line Items]
Total future milestone payments under license agreements with non-related parties	$ 50.8

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 USD ($) Lease	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Loss Contingencies [Line Items]
Number of operating leases | Lease	3
Lessee, operating lease, expiration period	We currently have three operating leases for administrative and research and development office and lab space in San Diego, California and Boston, Massachusetts that expire between July 2024 and November 2025.
Number of leases that include renewal option | Lease	2
Lease agreement additional extended lease term	5 years
Weighted-average discount rate	5.50%	5.50%
Weighted-average remaining lease term	2 years 3 months 18 days	3 years 3 months 18 days
Total cash paid for amounts included in the measurement of lease liabilities	$ 2,300,000	$ 2,100,000	$ 300,000
ROU assets obtained in exchange for operating lease liabilities	0	1,000,000	7,500,000
Total operating lease rent expense	2,000,000	2,000,000	2,000,000
ASC 842
Loss Contingencies [Line Items]
Total operating lease rent expense	2,000,000	$ 2,000,000	$ 1,700,000
San Diego Corporate Headquarters Lease
Loss Contingencies [Line Items]
Reimbursements for tenant improvements	1,000,000
Office Lease in Boston | Letter of Credit
Loss Contingencies [Line Items]
Letter of Credit	200,000
San Diego Lease for Lab and Office Space
Loss Contingencies [Line Items]
Reimbursements for tenant improvements	$ 100,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Loss Contingency [Abstract]
2023	$ 2,375
2024	1,863
2025	929
Total lease payments	5,167
Less: imputed interest	(301)
Total operating lease liabilities	$ 4,866

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended
	Nov. 30, 2022	Feb. 28, 2022	Dec. 31, 2020	May 31, 2020	Dec. 31, 2022	Dec. 31, 2020	Nov. 02, 2022
Stockholders' Equity Note [Abstract]
Common stock, shares issued			9,326,500	10,465,000
Common stock, issued price per share			$ 37	$ 13.75		$ 37
Proceeds from issuance of common stock, net			$ 324,100	$ 134,900	$ 24,721	$ 459,335
Loan and Security Agreement
Stockholders' Equity Note [Abstract]
Warrants issued to purchase of common stock					26,078
Warrants exercisable exercise price					$ 14.38		$ 14.38
Bristol Myers Squibb [Member] | Securities Purchase Agreement
Stockholders' Equity Note [Abstract]
Common stock, shares issued	1,370,171
Common stock, issued price per share	$ 18.25
Proceeds from issuance of common stock, net	$ 25,000
SVB Leerink LLC and Stifel, Nicolaus & Company, Incorporated | ATM Facility | Maximum
Stockholders' Equity Note [Abstract]
Aggregate offering price		$ 150,000
Term Loan | Oxford Finance LLC and Silicon Valley Bank
Stockholders' Equity Note [Abstract]
Warrants issued to purchase of common stock					33,988
Warrants exercisable exercise price					$ 3.31

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jan. 01, 2023	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense			$ 26,318	$ 23,579	$ 12,807
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
Closing price of common stock		$ 12.41	$ 12.41
Unrecognized estimated stock option compensation expenses		$ 44,700	$ 44,700
Weighted average service period			2 years 6 months
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
Unrecognized estimated RSUs compensation expenses		$ 9,800	$ 9,800
Weighted average service period			2 years 4 months 24 days
Maximum | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of options to be granted under the Plan			10 years
Amended and Restated 2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of increase in common shares reserved for future issuance pursuant to future grants			4%
Common shares available for future issuance pursuant to future grants		1,182,227	1,182,227
Amended and Restated 2014 Equity Incentive Plan | Common Stock | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for issuance		17,545,127	17,545,127
Amended and Restated 2014 Equity Incentive Plan | Subsequent Event
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional common shares reserved for future issuance pursuant to future grants	2,732,559
2015 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, Maximum number of share issuable			2,000,000
Share-based compensation expense			$ 300	$ 300	$ 200
Common shares available for future issuance pursuant to future grants		727,433	727,433
Employee stock purchase plan term of offering period			6 months
Percentage of maximum earnings withhold by employee to purchase shares		15%	15%
Percentage of common stock purchase			85%
Shares issued under ESPP		176,992
2015 Employee Stock Purchase Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of increase in common shares reserved for future issuance pursuant to future grants			1%
Approval by Stockholders at 2023 Annual Meeting of Stockholders | Scenario Forecast
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares available for future issuance pursuant to future grants						1,459,800

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Option Activities (Detail) - Stock Option $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, Beginning Balance, Number of Shares | shares	6,951
Granted, Number of Shares | shares	2,904
Exercised, Number of Shares | shares	(265)
Canceled, Number of Shares | shares	(1,165)
Stock Options Outstanding, Ending Balance, Number of Shares | shares	8,425
Vested and expected to vest, Number of Shares | shares	8,425
Exercisable, Number of Shares | shares	4,412
Outstanding, Beginning Balance, Weighted-Average Exercise Price per Share | $ / shares	$ 20.08
Granted, Weighted-Average Exercise Price per Share | $ / shares	14.51
Exercised, Weighted-Average Exercise Price per Share | $ / shares	14.16
Canceled, Weighted-Average Exercise Price per Share | $ / shares	21.69
Outstanding, Ending Balance, Weighted-Average Exercise Price per Share | $ / shares	18.12
Vested and expected to vest, Weighted-Average Exercise Price per Share | $ / shares	18.12
Exercisable, Weighted-Average Exercise Price per Share | $ / shares	$ 17.84
Outstanding, Weighted-Average Remaining Contractual Term (years)	7 years 7 months 6 days
Vested and expected to vest, Weighted-Average Remaining Contractual Term (years)	7 years 7 months 6 days
Exercisable, Weighted-Average Remaining Contractual Term (years)	6 years 8 months 12 days
Outstanding, Aggregate Intrinsic Value | $	$ 3,082
Vested and expected to vest, Aggregate Intrinsic Value | $	3,082
Exercisable, Aggregate Intrinsic Value | $	$ 2,860

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Information Regarding Stock Options (Detail) - Stock Option - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Cash received from options exercised	$ 3,756	$ 3,809	$ 9,766
Intrinsic value of options exercised	$ 701	$ 3,475	$ 13,348
Weighted-average grant date fair value per share	$ 8.90	$ 17.84	$ 10.15

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of RSU Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted Stock Units Outstanding, Beginning Balance, Number of Shares | shares	161
Granted, Number of Shares | shares	746
Released, Number of Shares | shares	(40)
Canceled, Number of Shares | shares	(99)
Restricted Stock Units Outstanding, Ending Balance, Number of Shares | shares	768
Expected to vest, Number of Shares | shares	768
Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value per Share | $ / shares	$ 32.80
Granted, Weighted Average Grant Date Fair Value per Share | $ / shares	13.70
Released, Weighted Average Grant Date Fair Value per Share | $ / shares	32.80
Canceled, Weighted Average Grant Date Fair Value per Share | $ / shares	17.68
Outstanding, Ending Balance, Weighted Average Grant Date Fair Value per Share | $ / shares	16.20
Expected to Vest, Weighted Average Grant Date Fair Value per Share | $ / shares	$ 16.20
Outstanding, Ending Balance, Weighted Average Remaining Vesting Period (years)	1 year 4 months 24 days
Expected to vest, Weighted Average Remaining Vesting Period (years)	1 year 4 months 24 days
Outstanding, Ending Balance, Aggregate Intrinsic Value | $	$ 9,541
Expected to Vest, Aggregate Intrinsic Value | $	$ 9,541

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Share-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 26,318	$ 23,579	$ 12,807
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	10,373	7,454	3,960
General and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 15,945	$ 16,125	$ 8,847

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of Estimate Fair Value of Stock Options and ESPP Stock Purchase Rights Using Black-Scholes Model (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility, Minimum	67.10%	72%	74.40%
Expected volatility, Maximum	71.90%	74.60%	76.10%
Risk free interest rate, Minimum	1.60%	0.60%	0.40%
Risk free interest rate, Maximum	4.20%	1.30%	2%
Stock Option | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years 5 months 12 days	5 years 6 months	5 years 6 months
Stock Option | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 6 months 25 days	6 years 29 days	6 years 29 days
2015 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 months	6 months	6 months
Expected volatility, Minimum	61%	44.80%	55.30%
Expected volatility, Maximum	75.80%	61.80%	91.90%
Risk free interest rate, Minimum	1.60%	0%	0.10%
Risk free interest rate, Maximum	4.60%	0.10%	0.90%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)		12 Months Ended			37 Months Ended
	Oct. 01, 2014	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020
Related Party Transaction [Line Items]
Total operating lease rent expense		$ 2,000,000	$ 2,000,000	$ 2,000,000
Araxes Pharma LLC | San Diego, California
Related Party Transaction [Line Items]
Sublease term		We subleased office space in San Diego, California from Araxes between June 2017 and June 2020.
Total operating lease rent expense				200,000
Araxes Pharma LLC | Monthly | San Diego, California | Minimum
Related Party Transaction [Line Items]
Rent expense, amended sublease					$ 16,000
Araxes Pharma LLC | Monthly | San Diego, California | Maximum
Related Party Transaction [Line Items]
Rent expense, amended sublease					$ 24,000
Araxes Pharma LLC | Management Fees
Related Party Transaction [Line Items]
Research and development services reimbursement, description		In addition, the agreement allows for Araxes to reimburse us an amount equal to the number of full-time equivalents, or FTE, performing research and development services for Araxes, plus actual expenses as reasonably incurred.
Management fee income, related party		$ 100,000	100,000	100,000
Reimbursements of research and development services		$ 0	0	0
Wellspring Biosciences Inc | Service Agreements
Related Party Transaction [Line Items]
Research and development services expense at full time equivalents rate	$ 400,000
Research and development expense payment, description		We have a services agreement with Wellspring Biosciences, Inc., or Wellspring, a wholly-owned subsidiary of Araxes, pursuant to which we pay Wellspring for research and development services provided to us in an amount equal to the number of FTE’s performing the services, at an annual FTE rate of $400,000, plus actual expenses as reasonably incurred. For the years ended December 31, 2022 and 2021, we did not recognize any expense under this service agreement.
Research and development, related party				100,000
ALG Partners, LLC | Service Agreements
Related Party Transaction [Line Items]
Research and development, related party		$ 0	$ 0	$ 100,000

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - Safe Harbor 401(k) Plan - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Contribution Plan Disclosure [Line Items]
Expenses related to contribution plan	$ 1.2	$ 1	$ 0.6
Maximum
Defined Contribution Plan Disclosure [Line Items]
Percent of employees compensation	4%	4%	3%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Significant Components Of Deferred Tax Assets And Liabilities [Line Items]
Provision for income taxes	$ 0	$ 0	$ 0
Effective federal statutory income tax rate, percent	21%	21%	21%
Increase in valuation allowance	$ 43,100,000
Income tax examination, likelihood of unfavorable settlement	An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Unrecognized interest and penalties	$ 0	$ 0	$ 0
Domestic Tax Authority
Significant Components Of Deferred Tax Assets And Liabilities [Line Items]
Net operating loss carryforrwards	$ 412,600,000
Loss carryforwards begin to expire	2034
Research and development credit carryforwards	$ 22,600,000
Credit carry forward begin to expire	2034
Domestic Tax Authority | Not Subject to Expiration
Significant Components Of Deferred Tax Assets And Liabilities [Line Items]
Net operating loss carryforrwards	$ 337,200,000
Domestic Tax Authority | Begin to Expire in 2034
Significant Components Of Deferred Tax Assets And Liabilities [Line Items]
Net operating loss carryforrwards	75,400,000
State and Local Jurisdiction
Significant Components Of Deferred Tax Assets And Liabilities [Line Items]
Net operating loss carryforrwards	572,000,000
Research and development credit carryforwards	5,400,000
State and Local Jurisdiction | Research and Development Credits
Significant Components Of Deferred Tax Assets And Liabilities [Line Items]
Credit carryforwards not subject to expiration	$ 3,000,000
State and Local Jurisdiction | Begin to Expire in 2030
Significant Components Of Deferred Tax Assets And Liabilities [Line Items]
Loss carryforwards begin to expire	2030
State and Local Jurisdiction | Begin to Expire in 2031 | Research and Development Credits
Significant Components Of Deferred Tax Assets And Liabilities [Line Items]
Credit carry forward begin to expire	2031
Credit carryforwards subject to expiration	$ 2,400,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income taxes at statutory federal rate	$ (28,526,000)	$ (27,398,000)	$ (18,821,000)
State income tax, net of federal benefit	(9,721,000)	(9,758,000)	(7,684,000)
Research and development tax credits	(6,970,000)	(5,850,000)	(3,169,000)
Share-based compensation	3,998,000	2,819,000	(304,000)
Other	(69,000)	(496,000)	(120,000)
Valuation allowance	41,288,000	40,683,000	30,098,000
Income tax expense	$ 0	$ 0	$ 0

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 125,986	$ 111,238
Research and development tax credit carryforwards	20,876	13,794
Section 174 capitalization	16,684
Share-based compensation	6,599	4,842
Accruals	2,713	2,096
Other comprehensive income	2,360	526
Operating lease liabilities	1,430	2,021
Other	1,018	562
Total gross deferred tax assets	177,666	135,079
Less: valuation allowance	(176,328)	(133,206)
Net deferred tax assets	1,338	1,873
Deferred tax liabilities:
Operating lease right-of-use assets	(1,129)	(1,638)
Other	(209)	(235)
Total gross deferred tax liabilities	(1,338)	(1,873)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Schedule of Acti

Income Taxes - Schedule of Activity Related to Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Gross unrecognized tax benefits at the beginning of the year	$ 4,402	$ 2,978	$ 1,741
Increases related to prior year tax positions	67	0	0
Increases from tax positions taken in the current year	2,016	1,424	1,237
Gross unrecognized tax benefits at the end of the year	$ 6,485	$ 4,402	$ 2,978